Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H1 2018
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H1 2018
SUMMARY
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 2, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Dermatology, Hematological Disorders, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Myelofibrosis, Atopic Dermatitis, Leukemias, Myeloproliferative Disorders, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alopecia, Glioblastoma Multiforme (GBM), Hematological Tumor, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bleeding And Clotting Disorders, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Eczema, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Failure, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular/Exudative) Macular Degeneration.
The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 2, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Dermatology, Hematological Disorders, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Myelofibrosis, Atopic Dermatitis, Leukemias, Myeloproliferative Disorders, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alopecia, Glioblastoma Multiforme (GBM), Hematological Tumor, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bleeding And Clotting Disorders, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Eczema, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Failure, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular/Exudative) Macular Degeneration.
The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celon Pharma SA
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
Nerviano Medical Sciences Srl
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
APL-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-13503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHZ-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPL-407105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
jaktinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-953 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-317461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Apr 25, 2018: Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Apr 23, 2018: FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Mar 09, 2018: CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Feb 14, 2018: Lilly to Showcase New Data for baricitinib at AAD Annual Meeting
Feb 12, 2018: Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
Jan 12, 2018: Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan
Jan 12, 2018: FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia Areata
Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials
Dec 10, 2017: Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi (ruxolitinib) in Patients with Polycythemia Vera
Nov 27, 2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting
Nov 15, 2017: Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi) for the Treatment of Essential Thrombocythemia
Nov 06, 2017: Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
Nov 05, 2017: ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
Nov 01, 2017: Incyte Highlights Jakafi Data at 59th Annual ASH Meeting
Oct 30, 2017: Lilly to Present New Data on its Anti-inflammatory Drug Candidate Baricitinib at ACR/ARHP Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celon Pharma SA
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
Nerviano Medical Sciences Srl
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
APL-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-13503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHZ-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPL-407105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
jaktinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-953 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-317461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Apr 25, 2018: Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Apr 23, 2018: FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Mar 09, 2018: CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Feb 14, 2018: Lilly to Showcase New Data for baricitinib at AAD Annual Meeting
Feb 12, 2018: Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
Jan 12, 2018: Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan
Jan 12, 2018: FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia Areata
Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials
Dec 10, 2017: Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi (ruxolitinib) in Patients with Polycythemia Vera
Nov 27, 2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting
Nov 15, 2017: Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi) for the Treatment of Essential Thrombocythemia
Nov 06, 2017: Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
Nov 05, 2017: ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
Nov 01, 2017: Incyte Highlights Jakafi Data at 59th Annual ASH Meeting
Oct 30, 2017: Lilly to Present New Data on its Anti-inflammatory Drug Candidate Baricitinib at ACR/ARHP Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aerie Pharmaceuticals Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Celon Pharma SA, H1 2018
Pipeline by Concert Pharmaceuticals Inc, H1 2018
Pipeline by CTI BioPharma Corp, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Japan Tobacco Inc, H1 2018
Pipeline by Nerviano Medical Sciences Srl, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by NS Pharma Inc, H1 2018
Pipeline by Simcere Pharmaceutical Group, H1 2018
Pipeline by Theravance Biopharma Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Dormant Products, H1 2018 (Contd.4), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aerie Pharmaceuticals Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Celon Pharma SA, H1 2018
Pipeline by Concert Pharmaceuticals Inc, H1 2018
Pipeline by CTI BioPharma Corp, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Japan Tobacco Inc, H1 2018
Pipeline by Nerviano Medical Sciences Srl, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by NS Pharma Inc, H1 2018
Pipeline by Simcere Pharmaceutical Group, H1 2018
Pipeline by Theravance Biopharma Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Dormant Products, H1 2018 (Contd.4), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Type, H1 2018
COMPANIES MENTIONED
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celon Pharma SA
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
Nerviano Medical Sciences Srl
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Type, H1 2018
COMPANIES MENTIONED
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celon Pharma SA
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Incyte Corp
Japan Tobacco Inc
Nerviano Medical Sciences Srl
Novartis AG
NS Pharma Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
